Gary Jacob
Chief Executive Officer at OKYO PHARMA LIMITED
Net worth: 69 134 $ as of 2024-05-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Brancaccio | M | 76 |
Callisto Pharmaceuticals, Inc.
 Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 20 years |
| Bernard Denoyer | M | 77 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 14 years |
| Willy Simon | M | 72 | 9 years | |
| Keeren Shah | F | 47 | 8 years | |
| Vanila Singh | M | 53 | 4 years | |
| Gabriele Cerrone | M | 52 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 14 years |
| Kaouthar Lbiati | M | 45 | 2 years | |
| John Cavan | M | 65 | 8 years | |
| Timothy Block | M | 69 | 11 years | |
| Michael Dubin | M | 68 | 3 years | |
| Paul Spencer | M | - | 2 years | |
| Raj Patil | M | 66 | 6 years | |
| Daniel Trepanier | M | - | 5 years | |
| Daren Ure | M | - | 5 years | |
| John Bell | M | 71 |
University of Oxford
| 35 years |
| Jules S. Jacob | M | - | 7 years | |
| William Clementi | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kunwar Shailubhai | M | 67 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 9 years |
| Hugh Grant | M | 65 | 20 years | |
| Robert Foster | M | 65 | 7 years | |
| Christopher Chipman | M | 50 | 3 years | |
| Craig C. Talluto | M | - |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 8 years |
| Richard Berman | M | 81 | 1 years | |
| James Sapirstein | M | 63 | 4 years | |
| Michael Barrow | M | - |
University of Oxford
| 3 years |
| Matt Greenwood | M | - |
University of Oxford
| 3 years |
| Julia Black | F | - |
University of Oxford
| 8 years |
| Kevin L. Thurm | M | 62 |
University of Oxford
| 1 years |
| Daniel Kapi | M | - |
University of Oxford
| 5 years |
| Philip Needleman | M | - |
G.D. Searle LLC
| 4 years |
| Man Wai Chiu | M | 55 |
University of Oxford
| 5 years |
| Yat Hung Fu | M | 60 |
University of Oxford
| 6 years |
| Ick-Soo Kim | M | 68 |
University of Oxford
| 3 years |
| Theresa Matkovits | M | 56 | 3 years | |
| Duraiswami Narain | M | 60 | 20 years | |
| Peter Wijngaard | M | 61 | 3 years | |
| Robin N. Lowe | M | 59 |
University of Oxford
| 4 years |
| Doron Junger | M | - |
University of Oxford
| 6 years |
| Antony J. Fairbanks | M | - |
University of Oxford
| 3 years |
| Rupert Charles de Borchgrave d'Altena | M | - |
University of Oxford
| 7 years |
| Christopher McGuigan | M | 65 | 3 years | |
| Simon H. Thomas | M | 64 |
University of Oxford
| 5 years |
| Judson A. Cooper | M | 65 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | - |
| Joshua D. Schein | M | 63 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | - |
| Randall K. Johnson | M | 77 |
Callisto Pharmaceuticals, Inc.
Callisto Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Callisto Pharmaceuticals, Inc. is a development stage biopharmaceutical company. The company operates through two subsidiary companies: Pharmaceuticals, Inc and Callisto Research Labs, LLC. It focuses primarily on the development of drugs to treat gastrointestinal disorder and diseases and rheumatoid arthritis and develops novel therapeutics to treat cancer. The company was founded by Judson A. Cooper and Joshua D. Schein in 1996 and is headquartered in New York, NY. | 8 years |
| Thomas H. Adams | M | 81 | 6 years | |
| Tamar Howson | F | 75 | 2 years | |
| William Guttman | M | 63 |
University of Oxford
| 5 years |
| Arnold Lippa | M | 77 | 8 years | |
| Anand Reddi | M | 42 | 2 years | |
| Shirley Cunningham | F | 63 | 15 years | |
| Stephen Swaffield | M | 61 |
University of Oxford
| 6 years |
| Byron Auguste | M | 56 |
University of Oxford
| 4 years |
| James Allen | M | 57 |
University of Oxford
| 5 years |
| AILSA HARRIS | F | - |
University of Oxford
| 4 years |
| Jih-Shian Yeo | M | 55 |
University of Oxford
| 4 years |
| Chee Peng Ng | M | 54 |
University of Oxford
| 4 years |
| Michael Stein | M | 60 |
University of Oxford
| 4 years |
| Brendan Ludden | M | - |
University of Oxford
| 5 years |
| Jason Bush | M | - |
University of Oxford
| 3 years |
| Duncan Fatkin | M | - |
University of Oxford
| 4 years |
| Nicola Kerslake | F | - |
University of Oxford
| 3 years |
| Guan Hong Yap | M | 60 |
University of Oxford
| 4 years |
| Diego Muñoz Tamayo | M | 67 |
University of Oxford
| 1 years |
| Ignatius Low | M | - |
University of Oxford
| 4 years |
| Steven Lang | M | - |
University of Oxford
| 3 years |
| Christine Whyte | M | - |
University of Oxford
| 4 years |
| Michael Hewett | M | - |
University of Oxford
| 3 years |
| Matthew Ridgwell | M | 59 |
University of Oxford
| 4 years |
| Steven Paul Frederick Ward | M | 53 |
University of Oxford
| 3 years |
| Emre Yigit | M | - |
University of Oxford
| 4 years |
| Maria Teresa H. D. S. M. Roque Dal Fabbro | F | - |
University of Oxford
| 3 years |
| Koosum P. Kalyan | F | 68 |
University of Oxford
| 4 years |
| Catherine Powell | F | 56 |
University of Oxford
| 4 years |
| Reid Hoffman | M | 56 |
University of Oxford
| 3 years |
| Philippa Aldrich | F | - |
University of Oxford
| 4 years |
| Simon Munton Bullivant | M | - |
University of Oxford
| 4 years |
| Carl Dunton | M | 52 |
University of Oxford
| 4 years |
| Eric Maisel | M | 58 |
University of Oxford
| 2 years |
| Mark Gallagher | M | - |
University of Oxford
| 4 years |
| Joshua Lewis | M | 62 |
University of Oxford
| 4 years |
| Chong Toh | M | 55 |
University of Oxford
| 4 years |
| Paul Markovich | M | - |
University of Oxford
| 2 years |
| Michael J. Buchanan | M | - |
University of Oxford
| 4 years |
| Matthew James Whittell | M | - |
University of Oxford
| 4 years |
| Andrew Edward Anson | M | 59 |
University of Oxford
| 3 years |
| Jonathan Hepple | M | 53 |
University of Oxford
| 3 years |
| Matthew Benson | M | 58 |
University of Oxford
| 4 years |
| Robert Baugh | M | - |
University of Oxford
| 4 years |
| Jeffrey Moore | M | - |
University of Oxford
| 4 years |
| Carolyn Anne Prowse | F | 52 |
University of Oxford
| 4 years |
| Christoph Matthias Widmer | M | 57 |
University of Oxford
| 4 years |
| Joanne Warner | M | 62 |
University of Oxford
| 3 years |
| Neill Penney | M | - |
University of Oxford
| 4 years |
| Eleni D. Dendrinou-Louri | M | 70 |
University of Oxford
| 4 years |
| Natalia Gurushina | M | - |
University of Oxford
| 5 years |
| James C. Clarke | M | - |
University of Oxford
| 4 years |
| Mark Brooker | M | 52 |
University of Oxford
| 4 years |
| Wai Keong Loh | M | - |
University of Oxford
| 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United Kingdom | 72 | 72.73% |
| United States | 32 | 32.32% |
| Australia | 1 | 1.01% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Gary Jacob
- Personal Network
